← Leaderboards
Mikell Paige
Georgetown University
$4,213,988
Attributed
$8,455,595
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2009–24$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,966,323 · 6
FDA$1,489,272 · 1
By mechanism
R01$7,440,968 · 3
R03$467,008 · 1
R43$447,945 · 2
R41$99,674 · 1
Top collaborators
- Kylene Kehn-Hall5 shared
- Dmitri Konstantinovich Klimov5 shared
- Yun Michael Shim5 shared
- Schroeder M Noble4 shared
- Cyrille Gineste2 shared
Most similar at Georgetown University
Same institution · by research overlap
- Jessica Morgan Jones$1,506,824
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculePharmaceutical PreparationsDesignIn VivoBaseAnimalsLeadModificationBindingNovel TherapeuticsPropertyMouse ModelSymptomsNeuronsAcuteInflammationLigandsGenerationsPreventMolecularMediatingIn VitroBiological AvailabilityLibraries
Grant awards (19)
Developing capsid-importin alpha inhibitors for the treatment of VEEV infection$708,202
R01 · FY2024 · AI · contact PI
Developing capsid-importin alpha inhibitors for the treatment of VEEV infection$679,799
R01 · FY2023 · AI · contact PI
Manufacturing and Characterization of Potent mRNA Lipid Nanoparticle Vaccines at Multiple Scales$498,828
R01 · FY2023 · FD · contact PI
Developing capsid-importin alpha inhibitors for the treatment of VEEV infection$687,849
R01 · FY2022 · AI · contact PI
Manufacturing and Characterization of Potent mRNA Lipid Nanoparticle Vaccines at Multiple Scales$491,446
R01 · FY2022 · FD · contact PI
Developing capsid-importin alpha inhibitors for the treatment of VEEV infection$718,061
R01 · FY2021 · AI · contact PI
Manufacturing and Characterization of Potent mRNA Lipid Nanoparticle Vaccines at Multiple Scales$498,998
R01 · FY2021 · FD · contact PI
Developing capsid-importin alpha inhibitors for the treatment of VEEV infection$764,337
R01 · FY2020 · AI · contact PI
Novel Class Therapy for IPF$223,276
R43 · FY2020 · HL
Discovery of New Anti-Inflammatory Agents to Treat COPD$583,478
R01 · FY2019 · HL · contact PI
Discovery of New Anti-Inflammatory Agents to Treat COPD$583,648
R01 · FY2018 · HL · contact PI
Drug Discovery for Idiopathic Pulmonary Fibrosis$224,669
R43 · FY2018 · HL
Discovery of New Anti-Inflammatory Agents to Treat COPD$606,053
R01 · FY2017 · HL · contact PI
Discovery of New Anti-Inflammatory Agents to Treat COPD$620,269
R01 · FY2016 · HL · contact PI
Application of CDX-MDM in Pre-Clinical Model of Murine Pulmonary Emphysema$99,674
R41 · FY2013 · HL · contact PI
Design and Synthesis of New Neuronal nAChR Silent Desensitizers for Drug Abuse$232,506
R03 · FY2010 · DA · contact PI
Design and Synthesis of New Neuronal nAChR Silent Desensitizers for Drug Abuse$19,602
R03 · FY2010 · DA · contact PI
Design and Synthesis of New Neuronal nAChR Silent Desensitizers for Drug Abuse$191,875
R03 · FY2009 · DA · contact PI
Design and Synthesis of New Neuronal nAChR Silent Desensitizers for Drug Abuse$23,025
R03 · FY2009 · DA · contact PI